Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial
PR Newswire•26/10/2026•08:30 ET
0
Key Highlights
- ➤Fifth cohort completed dosing at 1×10⁷ CAR-positive cells/kg, the trial’s highest dose level
- ➤First fifth-cohort patient maintained stable disease 90 days after treatment
- ➤Four patients surpassed one year post-treatment survival; one survived approximately 28 months
- ➤No dose-limiting toxicities observed across any cohort to date
- ➤Sixth cohort expected after routine 30-day safety verification, targeting 1×10(8) cells/kg
Expert Statements
Amit Kumar, Chairman and CEO of Anixa Biosciences
“Ovarian cancer remains one of the deadliest cancers affecting women, and patients with recurrent disease face limited treatment options and poor outcomes. While this Phase 1 study is primarily designed to evaluate safety, we are highly encouraged that the most recently evaluated patient maintained stable disease 90 days after treatment and multiple patients have surpassed one year of survival following treatment, with one patient having survived beyond two years. Typically, these highly pre-treated patients survive a matter of weeks. We look forward to further evaluating this novel solid tumor-specific CAR-T therapy as we continue to increase dosage to 1×10(8) CAR-positive cells per kilogram of body weight following lymphodepletion in the upcoming cohort.”
Anixa Biosciences Announces Completion of Treatment of Fifth Cohort in its Ovarian Cancer CAR-T Clinical Trial PR Newswire
First patient in fifth cohort exhibiting stable disease 90 days after treatment
Get started
Create a free account to read the full story.